Scientists have discovered that in certain circumstances the same DNA can lead to differential cell surface protein presentation on tumor vs. normal cells. When this occurs unique tumor-specific cell ...

Hi everyone! In today's #ASMR video I will be whispering your favorite trigger words and I will be doing it in inaudible and unintelligible whispering with some mouth sounds, hand movements and mic ...

Michael MacIntyre, MD, is a board-certified general and forensic psychiatrist practicing general psychiatry at the Veterans Affairs Healthcare System in Los Angeles. ASMR is a sensation in which ...

Antibody drug conjugates bring a targeted approach to the treatment of many types of cancer, but there’s still room for improving this class of therapies. This week, two startups revealed how they aim ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min CEO Jeff Landau said the $100 ...

Meghana Keshavan covers biotech and contributes to The Readout newsletter. Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. A ...

- Series A financing co-led by RA Capital, a16z Bio+Health and Nextech Invest, and includes participation from existing investors Emerson Collective Investments (managed by Yosemite), GV (Google ...

CAMBRIDGE, Mass., April 06, 2026 (GLOBE NEWSWIRE)-- Stipple Bio, Inc., a private biotechnology company harnessing epitope-level precision to create targeted cancer therapies, today announced the close ...

Newly uncloaked Stipple Bio is connecting the dots toward multiple early-stage clinical studies for its lead precision oncology asset, buoyed by a $100 million series A financing round. The “heavily ...

Stipple Bio Inc. raised $100 million in a series A financing to support progression of the company’s lead drug, STP-100, an antibody-drug conjugate that binds an undisclosed target, and the company’s ...